Joincare Pharmaceutical Group Industry Co., Ltd. Class A

Joincare Pharmaceutical Group Industry Co., Ltd. Class A

SSSE:600380
10.48
CNY
+0.04
(+0.38%)
1.26EPS
16.38P/E
18.59BMarket Cap
Apr 01Next Earn

Total Valuation

CNY

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A carries a market capitalization of 18.59B, placing it among publicly traded companies globally. Its enterprise value stands at 19.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap18.59B
Enterprise Value19.69B

Important Dates

Joincare Pharmaceutical Group Industry Co., Ltd. Class A's next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A has 1.83B shares outstanding.

Shares Outstanding1.83B

Valuation Ratios

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 16.38. The price-to-sales ratio is 1.38, and the price-to-book ratio stands at 1.30.

PE Ratio16.38
PS Ratio1.38
PB Ratio1.30
P/TBV Ratio1.63

Enterprise Valuation

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A trades at an EV/EBITDA multiple of 7.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 19.69B versus a market cap of 18.59B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.47
EV / EBITDA7.02
EV / EBIT7.02

Financial Position

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.99, indicating elevated leverage, while an interest coverage ratio of 41.10 demonstrates strong ability to service its debt obligations.

Current Ratio1.79
Quick Ratio1.13
Debt / Equity20.99
Debt / EBITDA1.69
Interest Coverage41.10

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A posted a return on equity (ROE) of 7.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.22, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.08, useful for judging operating efficiency across full business cycles. The company generates approximately 987,748.50 in revenue per employee across its workforce of 13,575.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times Joincare Pharmaceutical Group Industry Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)7.82
Return on Assets (ROA)3.22
Return on Invested Capital (ROIC)8.47
Return on Capital Employed (ROCE)0.08
Revenue Per Employee987,748.50
Employee Count13,575.00
Inventory Turnover2.35

Taxes

CNY

Over the twelve months ended September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A recorded 408.91M in income tax expense. That works out to an effective tax rate of 15.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.71B, leaving 1.13B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax408.91M
Effective Tax Rate15.10

Stock Price Statistics

CNY

As of the close on November 17, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A's stock has declined approximately 15.69% over the past 52 weeks. The 50-day moving average sits at 9.77, while the 200-day moving average is 10.41.

52-Week Price Change-15.69%
50-Day Moving Average9.77
200-Day Moving Average10.41

Income Statement

CNY

Over the twelve months ended September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A generated 13.41B in revenue and converted that into 1.13B in net income, yielding earnings per share of 1.26. EBITDA reached 2.80B, while operating income came in at 2.60B.

Revenue13.41B
Gross Profit7.86B
Operating Income2.60B
Pretax Income2.71B
Net Income1.13B
EBITDA2.80B
EBIT2.80B
Earnings Per Share (EPS)1.26

Balance Sheet

CNY

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A holds 11.88B in cash and equivalents against 4.73B in total debt, resulting in a net debt position of -7.20B. Total book value stands at 14.29B, with working capital of 8.35B providing operational flexibility.

Cash & Cash Equivalents11.88B
Total Debt4.73B
Net Debt-7.20B
Equity (Book Value)14.29B
Book Value Per Share7.81
Working Capital8.35B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-709.31M

Margins

Over the twelve months ended September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A posted a gross margin of 58.62, reflecting its pricing power and cost economics. The operating margin of 19.39 and net profit margin of 8.43 provide insight into operational efficiency.

Gross Margin58.62
Operating Margin19.39
Pretax Margin20.19
Profit Margin8.43
EBITDA Margin20.90

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A paid dividends of 0.60 per share. The dividend payout ratio of 31.79 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 16.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Joincare Pharmaceutical Group Industry Co., Ltd. Class A shareholders.

Dividend Per Share0.60
Payout Ratio31.79
Shareholder Yield16.49

Stock Splits

Joincare Pharmaceutical Group Industry Co., Ltd. Class A's most recent stock split took place on October 16, 2018 with a 923:1020 split ratio.

Last Split Date10/16/2018
Split Ratio923:1020

Scores

As of September 30, 2026, Joincare Pharmaceutical Group Industry Co., Ltd. Class A has an Altman Z-Score of 2.39, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.39